EU drug regulator OKs Pfizer Covid pill for high-risk patients
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Tuesday
January 31, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
TUESDAY, JANUARY 31, 2023
EU drug regulator OKs Pfizer Covid pill for high-risk patients

Coronavirus chronicle

Reuters
28 January, 2022, 10:40 am
Last modified: 28 January, 2022, 10:54 am

Related News

  • WHO 'strongly recommends' Pfizer's Covid pill
  • Demand for Pfizer's Covid pills lags around the world
  • Pfizer to maintain drug supply to Russia
  • Biden announces new Covid initiative that gives Americans free pills
  • S Korea authorises Novavax Covid-19 vaccine, imports Pfizer pills

EU drug regulator OKs Pfizer Covid pill for high-risk patients

EU health commissioner Stella Kyriakides said the bloc was now making good progress on lining up treatments, which she described as a second line of defence after vaccines

Reuters
28 January, 2022, 10:40 am
Last modified: 28 January, 2022, 10:54 am
Paxlovid, a Pfizer's coronavirus disease (Covid-19) pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on 16 November, 2021. PHOTO: Pfizer/Handout via REUTERS
Paxlovid, a Pfizer's coronavirus disease (Covid-19) pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on 16 November, 2021. PHOTO: Pfizer/Handout via REUTERS

The European Union's drug regulator on Thursday gave the green light to Pfizer Inc's antiviral Covid-19 pill for treating adults at risk of severe illness, as the region scrambles to boost its arsenal to fight the Omicron variant.

The endorsement by the European Medicines Agency (EMA) for a conditional approval, if followed as usual by the European Commission, allows EU member states to deploy the drug after the regulator gave guidance for its emergency use late last year.

Italy, Germany and Belgium are among a handful of EU countries that have bought the drug, branded as Paxlovid.

The United States in December authorised Paxlovid and Merck's similar drug molnupiravir. 

EU health commissioner Stella Kyriakides said the bloc was now making good progress on lining up treatments, which she described as a second line of defence after vaccines.

"Paxlovid is the first oral antiviral for home use in our portfolio, and has the potential to make a real difference for persons at high risk of progression to severe Covid," she said.

Merck's pill is also under review in the EU, but is taking longer to approve because the company revised its trial data in November, saying the drug was significantly less effective than previously thought.

These oral drugs, especially Pfizer's, are seen as promising new treatment options that can be taken at home at the onset of Covid-19 symptoms to help prevent hospitalizations and deaths.

"We are proud to have a strong manufacturing footprint in Europe, which will help support the production of up to 120 million courses of Paxlovid globally," Pfizer Chief Executive Albert Bourla said in a statement.

Paxlovid, a two-drug antiviral regimen, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retained its effectiveness against the Omicron variant as well.

In the trial however, it was only tested on unvaccinated individuals, raising questions on its potential use in high-risk patients who did get inoculated. EMA did not limit its endorsement to the non-vaccinated.

Germany ordered 1 million courses late in December. Health Minister Karl Lauterbach said on Jan. 2 he expected the country's drug regulator to give a national emergency go-ahead before the end of the month and that rollout would start then.

Italy will receive 200,000 courses in February and has the option to buy an additional 400,000.

Top News / World+Biz

antiviral Covid-19 pill / pfizer pill / Pfizer oral drug / Merck Covid-19 Pill

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • illustration: TBS
    Bangladesh's GDP growth to stay below pre-pandemic level even in FY27: IMF
  • Representational photo: TBS
    IMF's blueprint for Bangladesh's upper middle income goal
  • Representational Image
    Dhaka underground metro rail: Airport-Kamalapur in just 25 minutes

MOST VIEWED

  • People walk outside wearing masks during the coronavirus disease (COVID-19) pandemic in the Harlem area of the Manhattan borough of New York City, New York, U.S., February 10, 2022. REUTERS/Carlo Allegri
    US to end Covid-19 emergency declarations on 11 May
  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs
  • Photo: Collected
    India launches world’s 1st intranasal Covid vaccine
  • A vial of the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot

Related News

  • WHO 'strongly recommends' Pfizer's Covid pill
  • Demand for Pfizer's Covid pills lags around the world
  • Pfizer to maintain drug supply to Russia
  • Biden announces new Covid initiative that gives Americans free pills
  • S Korea authorises Novavax Covid-19 vaccine, imports Pfizer pills

Features

Photo: Collected

Tips to incorporate sustainable construction

4h | Habitat
Photo: Noor-A-Alam

How did mud walls find their way into urban designs?

5h | Habitat
Spotify is among the tech platforms that saw record growth during Covid lockdowns
Photo: DW

Could tech layoffs spread to rest of US economy?

9h | Panorama
Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected

'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

9h | Panorama

More Videos from TBS

Sunflower cultivation is becoming popular in Faridpur

Sunflower cultivation is becoming popular in Faridpur

1h | TBS Stories
Is Djokovic the statistical G.O.A.T?

Is Djokovic the statistical G.O.A.T?

2h | TBS SPORTS
Two more factories of the country got platinum certificate.

Two more factories of the country got platinum certificate.

20h | TBS Today
Iconic villains of Bollywood

Iconic villains of Bollywood

21h | TBS Entertainment

Most Read

1
Bapex calls candidates for job test 9 years after advert!
Bangladesh

Bapex calls candidates for job test 9 years after advert!

2
Illustration: TBS
Banking

16 banks at risk of capital shortfall if top 3 borrowers default

3
Representational Image
Banking

Cash-strapped Islami, Al-Arafah and National turn to Sonali Bank for costly fund

4
Photo: Collected
Energy

8 Ctg power plants out of production

5
Photo: Saqlain Rizve
Bangladesh

Bangladeshi university students identified as problematic users of Facebook, internet: Study

6
Photo: Collected
Splash

Hansal Mehta responds as Twitter user calls him 'shameless' for making Faraaz

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net